GW Pharmaceuticals plc: 02/02/2016 GW Pharmaceuticals to Report Q1 Financial Results and Host Conference Call on 10 February, 2016

Tickers: GWPH
f96a1a40-99ab-4577-941e-bb2f8d2a5d38.pdf

February 2, 2016

Top Company Interviews

Microsoft Corporation
Intel Corporation
Pfizer, Inc.
General Electric Company
Wal-Mart Stores, Inc.

GW Pharmaceuticals to Report Q1 Financial Results and Host Conference Call on 10 February, 2016


LONDON, Feb. 02, 2016 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) ("GW" or "the Company"), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, will announce on 10 February, 2016 its first quarter financial results for the period ending 31 December, 2015. GW will also host a conference call the same day at 8:00 a.m. EST (1:00 p.m. GMT).

Conference call information will be provided in the financial results press release. A replay of the call will also be available through the Company's website (www.gwpharm.com) shortly after the call.


About GW Pharmaceuticals plc


Founded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. GW commercialized the world's first plant-derived cannabinoid prescription drug, Sativex®, which is approved for the treatment of spasticity due to multiple sclerosis in 28 countries outside the United States. GW is advancing an orphan drug program in the field of childhood epilepsy with a focus on Epidiolex® (cannabidiol), which is in Phase 3 clinical development for the treatment of Dravet syndrome and Lennox-Gastaut syndrome and which is also expected to enter Phase 3 clinical trials in the treatment of Tuberous Sclerosis Complex. GW has a deep pipeline of additional cannabinoid product candidates which includes Sativex in Phase 3 clinical development as a potential treatment of pain associated with advanced cancer, as well as compounds in Phase 1 and 2 trials for glioma, type 2 diabetes, and schizophrenia. For further information, please visit www.gwpharm.com.


Enquiries:


GW Pharmaceuticals plc (Today) +44 20 3727 1000

Stephen Schultz, VP Investor Relations (U.S.) 917 280 2424 / 401 500 6570


FTI Consulting (Media Enquiries)

Ben Atwell / Simon Conway + 44 20 3727 1000

GW Pharmaceuticals plc issued this content on 02 February 2016 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 02 February 2016 15:12:11 UTC

Original Document: http://ir.gwpharm.com/common/download/download.cfm?CompanyID=AMDA-1TW341&FileID=872889&FileKey=FC5737AD-21D5-4F84-A612-1F3BD4645B58&FileName=GWPH_News_2016_2_2_All_News_Types.pdf